Reduced duration and dosage of venetoclax is efficient in newly diagnosed patients with acute myeloid leukemia

Reduced duration and dosage of venetoclax is efficient in newly diagnosed patients with acute myeloid leukemia

Objectives The combination of Venetoclax (VEN) and Azacitidine (AZA) increases survival outcomes and yields excellent responses in patients with acute myeloid leukemia (AML). However, dose reduction (or discontinuation) is commonly encountered due to therapy-related toxicity. Thus, this study aimed...

Full description

Saved in:
Bibliographic Details
Main Authors: Jingying Cui, Xuexing Chen, Chunfang Li, Qiong Yan, Guolin Yuan
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Hematology
Subjects:
Venetoclax
azacytidine
dose and duration optimization
acute myeloid leukemia
myelosuppression management
Newly diagnosed
Online Access:https://www.tandfonline.com/doi/10.1080/16078454.2023.2293512
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items